Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Jhaveri and colleagues also evaluated imlunestrant in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) versus ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion. VERZENIO (abemaciclib ...